Phreesia stock
PHRNYSEPhreesia, Inc., HealthcareISIN US71944F1066
55Score 55 out of 100, Neutral
Price and trend
88 / 100
Price history
−45% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 45% below its 52-week high. Largest decline in 7 years: 90% (February 2021 to April 2026).
Chart figures for advanced users
- SMA 50$11.20
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.79
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.06
- The lowest closing price of the last twelve months.
- Resistance$23.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Phreesia, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $783.33M, is number 17 of 25 companies in its industry on MEQIRI.
- For fiscal 2027, analysts expect on average revenue of $515.73M (up 7.3%) and adjusted earnings per share of $0.29 (up 378.6%).
- MEQIRI Score 55 out of 100 (Neutral): rank 336 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $32.69, with the price 61% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.
- Growing faster than its industryRevenue up 26.4% a year since 2021, Medical (Healthcare Information Services) median 16.5%.Growth 70
- Below fair valuePrice 61% below the fair value of $32.69.Valuation 65
Weaknesses
- DilutionShare count up 51% since 2021.Capital allocation 28
- Share price fell sharplyDown 45% over the last 12 months.Momentum 60
- Volatile share priceVolatility 59% a year over the last 12 months.Stability 54
Its standout strengths are technical analysis and growth, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
- price far below its 52-week high
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $23.35 and expensive above $54.49 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $58.19 (cash-flow model) and $7.20 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $27.47, at 7.8% it would be $40.56.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (43).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Jul 2026, revenue rose 12.9% on the twelve months before. Revenue has grown strongly since 2018, at around 25% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 68%, operating −1%, net 0%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Dec 2026in 20 days
- Last reported
- 2 Sep 2026EPS reported $0.03 (expected $0.09)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.29−1.8%
- Revenue
- $515.73M0.0%
- Earnings per share
- $0.66+1.2%
- Revenue
- $537.1M+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −6.3%Guidance maintained: fiscal 2027 revenue of $510 million to $520 million and adjusted EBITDA of $125 million to $135 million.
“We are maintaining our adjusted EBITDA outlook for fiscal 2027 at a range of $125 million to $135 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 2 Sep 2026 (fiscal Q2 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $683 in total. 3 insiders sold, $129,445 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Linetsky DavidPurchase
22 Oct 2026, President, Network Solutions
- Shares
- 70
- Price
- $9.75
- Value
- $683
- Hoffman Allison CSale
21 Sept 2026, General Counsel & Secretary
- Shares
- 6,662
- Price
- $10.08
- Value
- $67,153
- Hui YvonneSale
16 Jul 2026, Principal Accounting Officer
- Shares
- 1,247
- Price
- $10.92
- Value
- $13,617
Show 4 more
- Egbuonu-Davis LisaSale
14 Jul 2026, Board
- Shares
- 536
- Price
- $10.70
- Value
- $5,735
- Hui YvonneSale
6 Jul 2026, Principal Accounting Officer
- Shares
- 1,371
- Price
- $10.84
- Value
- $14,862
- Egbuonu-Davis LisaSale
25 Jun 2026, Board
- Shares
- 2,546
- Price
- $9.53
- Value
- $24,263
- Hui YvonneSale
18 May 2026, Principal Accounting Officer
- Shares
- 431
- Price
- $8.85
- Value
- $3,814
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Phreesia
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- Teladoc HealthTDOC $1.63B47
- GoodRx HoldingsGDRX $1.25B58
- Omada HealthOMDA $945.45M44
- HealthStreamHSTM $883.61M62
- SOPHiA GENETICSSOPH $635.9M47
- RaySearch LaboratoriesRAY-B.ST $587.54M66
- NRC HealthNRC $570.01M59
- Evolent HealthEVH $561.28M45
ETFs that hold Phreesia
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 0.67% | 0.68% | €5.31M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.35% | €434.1M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.00% | 0.43% | €2.48B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.